Status:
COMPLETED
Mineralocorticoid Receptor in the Treatment of Severe Depression
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Conditions:
Major Depression
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The proposed research aims to compare the onset of action and the efficacy of fludrocortisone, a mineralocorticoid receptor agonist vs. spironolactone, a mineralocorticoid antagonist, vs. placebo as a...
Eligibility Criteria
Inclusion
- Depressed male and female inpatients according to DSM-IV
- Age between 18 and 70 years
- Minimum of 17-items Hamilton Depression Score of 18
- Informed consent signed
Exclusion
- Relevant medical or neurological disorders
- Pregnancy or unsure contraception
- Relevant psychiatric comorbidity
- Active alcohol or other substance abuse/dependance
- Contraindications to SSRI, fludrocortisone, or spironolactone
- Steroid medication
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00295347
Start Date
December 1 2005
End Date
June 1 2008
Last Update
May 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Hamburg-Eppendorf
Hamburg, Germany, 20246